MLI Certified

On-Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
The Evolution of HCT, Part 5: Shared Care
  • Credit: 0.75hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 5 in a 5-part series, exploring how shared and coordinated care between transplant centers and hematology/oncology practices can help overcome barriers to HCT and improve patient outcomes and experience.
Access Course
  • On-Demand
Keeping Up with CAR T-cell Therapy: A Case-based Challenge of CART in NHL + MM
  • Credit: 1.50hr(s)
  • ILNA, NCPD
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: Hematology, Lymphoma, Oncology
  • Location: Internet Activity Enduring
Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.
Access Course
  • On-Demand
Setting Up Patients for HCT and Cell Therapy Success
  • Credit: 1.00hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
This self-guided course provides practical recommendations and guidance on what hematology/oncology practices can do to improve patient experience and outcomes before their patient reaches a transplant center for consultation for Hematopoietic Cell Transplantation (HCT).
Access Course
  • On-Demand
DIABESITY DIALOGUES: Patient Perspectives for PCPs - Tackling the Treatment Paradigms of Obesity, T2D, and Other Metabolic Disorders
  • Credit: 1.00hr(s)
  • AAPA, CDCES, CME, CPE, IPCE, NCPD
  • June 9, 2023 — 
  • June 8, 2024
  • Therapeutic Areas: Diabetes, Obesity
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
There is an urgent need for effective intervention by healthcare professionals (HCPs) to address the twin epidemics of Type 2 diabetes (T2D) and obesity. Tune into the Diabesity Dialogues vodcast, where renowned physicians, Dr. Robert Kushner, MD, and Dr. Jamy Ard, MD, provide valuable insights on treatment initiation, intensification, and the effective management of diabesity in the presence of other comorbidities. Hear how our esteemed hosts harness the power of social media and discuss the latest information on GLP-1 receptor agonists (RA) and dual GIP/GLP-1 RAs and dispel potential misinformation. In this special feature, tune into patient voices from social media and learn practical tips to enhance patient-centered care and be at the forefront of transformative practices. Don’t miss this opportunity to join this cutting-edge conversation.
Access Course
  • On-Demand
Build Your Own Case Study | From Evidence to Practice: Enhancing T2D Outcomes with Informed Approaches on Obesity
  • Credit: 0.98hr(s)
  • AAPA, CME, EBAH, ECMEC, IPCE, MOC, NCPD
  • January 15, 2024 — 
  • January 14, 2025
  • Therapeutic Areas: Diabetes, Endocrinology
  • Specialties: Diabetes, Endocrinology, Obesity, Primary Care
  • Location: Internet Activity Enduring
The tie between type 2 diabetes (T2D) and overweight/obesity is a significant global public health issue, supported by decades of extensive research. Despite formal clinical guidelines recommendations in addressing both diseases, the initiation or intensification of therapies that improve glycemic control and achieve weight reduction targets are slowly adopted into clinical practice, particularly for patients with T2D. Given the overlap of these two conditions, it is imperative that healthcare providers worldwide align clinical practice with evidence-based guidelines and the latest clinical findings using newer agents to treat both diseases.
Access Course
  • On-Demand
Effective Strategies for Improving Vaccine Uptake
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC, NCPD, Royal College MOC 
  • June 28, 2024 — 
  • June 27, 2025
  • Therapeutic Areas: Family Medicine / Primary Care
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges in vaccine acceptance. A critical need exists among primary care providers (PCPs) to remain abreast of the continuously evolving vaccination landscape. As such, PCPs need to be able to evaluate the burden of vaccine-preventable diseases, provide well-founded recommendations for vaccine measures, and apply appropriate strategies to address vaccine hesitations.
Access Course
  • On-Demand
New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
  • Credit: 1.00hr(s)
  • AAPA, CME, CPE, IPCE, NCPD
  • May 31, 2023 — 
  • May 30, 2024
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: CAR T-Cell Therapy, Multiple Myeloma
  • Location: Internet Activity Enduring
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.
Access Course
  • On-Demand
Bridging the Gap to Reach Treatment Goals in DLBCL
  • Credit: 1.0hr(s)
  • AAPA, CME, CPE, NCPD
  • March 15, 2023 — 
  • February 28, 2024
  • Therapeutic Areas: Hematologic Oncology, Hematology
  • Specialties: CAR T-Cell Therapy, Lymphoma
  • Location: Internet Activity Enduring
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment. Join us for this educational Med Table Talk® LIVE on Bridging the Gap to Reach Treatment Goals in DLBCL as our experts have a candid conversation about the available treatment options for DLBCL, how cellular therapists and community physicians must communicate to ensure adequate care between referring and treating physicians, and how to recognize and address common treatment barriers. This taped satellite symposium was derived from the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR® on February 18, 2023.
Access Course
  • On-Demand
Time Well Spent: Treating Obesity and Diabetes
  • Credit: 1.0hr(s)
  • AAPA, CME, NCPD
  • November 10, 2023 — 
  • November 9, 2024
  • Therapeutic Areas: Family Medicine / Primary Care
  • Specialties: Diabetes, Obesity, Primary Care
  • Location: Internet Activity Enduring
Community Collective: Time Well Spent – Navigating the Challenges of Treating Obesity and Diabetes is an educational curriculum designed for rural primary care clinicians to enhance outcomes for individuals with obesity through improved diagnosis and use of therapy options to treat type 2 diabetes (T2D).
Access Course
  • On-Demand
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • February 17, 2023 — 
  • September 30, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: NSCLC, Oncology
  • Location: Internet Activity Enduring
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points to metastatic NSCLC (mNSCLC) patient cases while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in mNSCLC and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 1 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies for an in-depth dive into the data!
Access Course
  • On-Demand
Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies
  • Credit: 0.50hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD, Royal College MOC 
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Pan Tumor, Pathology, Pharmacy
  • Specialties: Pathology, Pharmacy
  • Location: Internet Activity Enduring
In this second episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty on how to select CAR T-cell and bispecific antibody treatment regimens for NHL according to the latest clinical evidence including safety and efficacy data in accordance with clinical guidelines. Additionally, expert faculty will discuss how to best identify patients who are candidates for CAR T-cell or bispecific antibody therapies as well as how to evaluate the potential of bridging therapy in patients awaiting CAR T-cell therapy. Finally, expert faculty will review treatment-related toxicities with strategies and educational tools that can be used to prevent, monitor, and manage adverse events. This episode will conclude with a discussion between expert faculty and a special guest, Caitlin Murphy, DNP.
Access Course
  • On-Demand
Weight Management as a Treatment for T2D: Novel Pharmacological Approaches
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC
  • April 30, 2024 — 
  • October 31, 2025
  • Therapeutic Areas: Diabetes, Family Medicine / Primary Care, Obesity
  • Specialties: Diabetes, Endocrinology, Obesity, Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Access Course
  • On-Demand
The Evolution of HCT, Part 3: Donor Availability
  • Credit: 0.75hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
Access Course
  • On-Demand
The Burden of Vaccine-Preventable Disease: Assessing Risk in Older Adults
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC, NCPD, Royal College MOC 
  • June 28, 2024 — 
  • June 27, 2025
  • Therapeutic Areas: Family Medicine / Primary Care
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges in vaccine acceptance. A critical need exists among primary care providers (PCPs) to remain abreast of the continuously evolving vaccination landscape. As such, PCPs need to be able to evaluate the burden of vaccine-preventable diseases, provide well-founded recommendations for vaccine measures, and apply appropriate strategies to address vaccine hesitations.
Access Course
  • On-Demand
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
  • Credit: 1.0hr(s)
  • ABIM, CME, IPCE, MOC, NCPD, Royal College MOC 
  • June 15, 2024 — 
  • June 14, 2025
  • Therapeutic Areas: Chronic Lympoblastic Leukemia (CLL)
  • Specialties: Mantle Cell Lymphoma
  • Location: Internet Activity Enduring
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided with patient clinical presentation and other relevant factors including age, time and aggressiveness of relapse, social history, genetic profiling/molecular testing results, cytogenetic risk factors, disease subtype, comorbidities, and prior therapies in order to make appropriate treatment decisions. Expert faculty will discuss participant selection of treatments, sequencing considerations, and drug-related toxicities. The activity will conclude with a discussion on how to develop strategies to assist patients with coordinated care and long-term disease management after the receipt of CAR T-cell therapy. This ancillary educational activity is derived from the 2024 ASCO Annual Meeting, originally held on May 31, 2024
Access Course
  • On-Demand
The Evolution of HCT, Part 1: Basics and Outcomes
  • Credit: 1.50hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 1 in a 5-part series, including the series introduction, basics of HCT, and major advances in HCT outcomes over time.
Access Course
  • On-Demand
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Improving Collaboration Amongst Multidisciplinary Teams to Tackle OSA
  • Credit: 0.50hr(s)
  • AAFP, AAPA, CME, MOC
  • March 6, 2024 — 
  • March 5, 2025
  • Therapeutic Areas: Family Medicine / Primary Care
  • Location: Internet Activity Enduring
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape.
Access Course
  • On-Demand
Advances in Non-Hodgkin Lymphoma Care: Navigating New and Emerging Treatments
  • Credit: 0.25hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD, Royal College MOC 
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Pan Tumor, Pathology, Pharmacy
  • Specialties: Pathology, Pharmacy
  • Location: Internet Activity Enduring
In this first episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty about unmet needs for patients with NHL based on an understanding of disease- and patient-related characteristics. Additionally, learn how to best assess eligible patients among new and emerging CAR T-cell and bispecific antibody therapies. Expert faculty will also discuss both the mechanisms of action of CAR T-cell and bispecific antibodies. This episode will conclude with a patient case study, which will consist of a dialogue between faculty.
Access Course
  • On-Demand
Understanding the Impact of Weight on T2D Outcomes
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC
  • April 30, 2024 — 
  • October 31, 2025
  • Therapeutic Areas: Diabetes, Family Medicine / Primary Care, Obesity
  • Specialties: Diabetes, Endocrinology, Obesity, Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Access Course
  • On-Demand
The Evolution of HCT, Part 2: Eligibility
  • Credit: 0.75hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 2 in a 5-part series, covering advances that have expanded eligibility for HCT and considerations for who is a candidate.
Access Course
  • On-Demand
Integrating Novel Therapies in Hemophilia in the Midst of Bridging Health Inequities
  • Credit: 1.0hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: Hematology, Lymphoma, Oncology
  • Location: Internet Activity Enduring
As the treatment armamentarium for patients with hemophilia continues to expand, there is an urgent need for healthcare providers to stay up-to-date on the latest advances so that they are prepared to integrate them into clinical practice. To bridge this gap, this interactive educational activity will provide a review of the science surrounding new and emerging hemophilia treatments and their mechanisms of action; recent safety and efficacy data from key clinical trials; and novel dosing strategies to mitigate adverse events. Engaging case-based discussions and insights on addressing common patient barriers and clinical challenges will be explored by expert faculty, including a guest spotlight offering the early perspective.  Thus, this educational initiative is designed to equip providers with the necessary tools to effectively navigate new and novel therapies, overcome patient-level barriers, and optimize adherence for improved patient outcomes.
Access Course
  • On-Demand
Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health - Screening and Management of OSA
  • Credit: 0.50hr(s)
  • AAFP, AAPA, CME, MOC
  • February 21, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Family Medicine / Primary Care
  • Location: Internet Activity Enduring
Obstructive Sleep Apnea (OSA) is a prevalent but often underestimated sleep disorder with significant implications for the health and well-being of individuals in the United States. Despite its impact on chronic diseases and healthcare costs, OSA remains underdiagnosed, leading to untreated sleep apnea and its consequences. With emerging strategies for OSA treatment, it’s crucial for healthcare providers to stay informed about the latest clinical evidence shaping the treatment landscape. Explore the 3-part on-demand series, Breathing Easy: Conquering Obstructive Sleep Apnea for Better Health. This collaborative effort, in conjunction with local AAFP Chapter meetings, provides expert guidance and clinical best practices for screening, managing, monitoring, and treating patients with OSA
Access Course
  • On-Demand
Impact of Prevention: Updates in Vaccine Development
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC, NCPD, Royal College MOC 
  • June 28, 2024 — 
  • June 27, 2025
  • Therapeutic Areas: Family Medicine / Primary Care
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges in vaccine acceptance. A critical need exists among primary care providers (PCPs) to remain abreast of the continuously evolving vaccination landscape. As such, PCPs need to be able to evaluate the burden of vaccine-preventable diseases, provide well-founded recommendations for vaccine measures, and apply appropriate strategies to address vaccine hesitations.
Access Course
  • On-Demand
Checkpoint Conversations: Integrating Immune Checkpoint Inhibitors in Hodgkin Lymphoma
  • Credit: 0.51hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD, Royal College MOC 
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Pan Tumor, Pathology, Pharmacy
  • Specialties: Pathology, Pharmacy
  • Location: Internet Activity Enduring
In this fourth episode, “Checkpoint Conversations: Integrating Immune Checkpoint Inhibitors in Hodgkin Lymphoma,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” join expert faculty as they discuss the benefit of immune checkpoint inhibition for the treatment of HL in patients with relapsed/refractory disease. Discussions will also circulate around how interdisciplinary teams can assist with coordination of patient care, including clinical trials and access to appropriate treatment for those in underrepresented communities.
Access Course
Scroll to Top